Nausea, fullness and food
Quick answer. Nausea is the most common side effect of GLP-1 medicines. In the Wegovy trials 44% of people reported it versus 16% on placebo, and in the Zepbound trials 25% to 29% versus 8%. Expert groups suggest smaller, more frequent meals, avoiding fatty food in the first days of a new dose, and not letting long gaps go by without eating. No trial has tested those food changes on their own.
Why it happens
These medicines slow how fast the stomach empties, and they act on parts of the brain that control appetite and nausea. That is the same action that makes you feel full sooner, so fullness and nausea often arrive together. They are most likely when you start and each time the dose goes up.
A 2023 expert consensus of endocrinologists, kidney specialists, primary care doctors, cardiologists, internists and a diabetes nurse educator reviewed the trial data. It reports that digestive side effects develop in roughly 40% to 70% of people treated, are usually mild to moderate, and mostly start during the dose-raising period. For nausea, it reports a range of 15% to 50% across trials, highest in the first four to five weeks, with episodes usually fading within about 8 days of starting.
Those figures describe groups of people, not you. Some people never feel sick, and some have a harder time.
What trials show
The official labels give the clearest numbers. In the Wegovy trials, nausea was reported by 44% of people on 2.4 mg versus 16% on placebo, vomiting by 24% versus 6%, and stopping because of digestive reactions happened in 4.3% versus 0.7%. In the Zepbound trials nausea was 25% at 5 mg, 29% at 10 mg and 28% at 15 mg, versus 8% on placebo, and stopping because of digestive reactions was 1.9% to 4.3% versus 0.5%.
A 2025 analysis of the four SURMOUNT tirzepatide trials found that most digestive events were mild to moderate and clustered around the dose-raising period. People who felt nausea lost about the same amount of weight as people who did not. In SURMOUNT-1 at 72 weeks those with no nausea lost 19.7% of their weight and those with nausea alone lost 22.0%. The authors estimated side effects explained up to about 3% of total weight loss. It was a post hoc analysis funded by the manufacturer, so it shows a pattern and does not prove cause.
In those trials, people with intolerable symptoms were first counseled to eat smaller meals, spread the day over four or more small meals, and stop when full. Investigators could then add medicine for nausea, skip a weekly dose or lower the dose a step. This is how the trials handled the problem, and the analysis does not measure how much each step helped.
The Atlas did not find a randomized trial that tested a specific food change, such as ginger, small meals or bland food, against nothing in people taking these medicines.
What experts say about nausea and food
The 2025 advisory from four U.S. nutrition and obesity societies says nausea often happens in the morning or after a long stretch without eating. Its suggestions are smaller, more frequent meals, and avoiding fatty or high-fiber foods for the first few days of treatment. It says vomiting is more likely after large meals.
It also describes a trap. Some people stop eating because of nausea, which makes the nausea worse and lowers the chance of eating later. For that situation the advisory suggests breakfast followed by a small meal every 3 to 4 hours while drinking enough fluid. It lists ginger or peppermint tea and acupressure bands as things that can help, and says anti-nausea medicine is an option while people adjust and during dose increases.
On foods that move through the stomach more easily, the advisory points to thin liquids, lower-calorie foods, lower glycemic index foods and foods high in moisture, such as low-fiber vegetables and fruit. Foods high in protein, fat or fiber slow the stomach more. That can help with fullness and weight loss and can also make symptoms worse, so the advisory says those foods may need to be cut back for a while.
The 2023 consensus recommends starting at the lowest dose and following the escalation schedule. If vomiting or nausea does not settle, it says a lower dose or a temporary pause may be considered, and switching to a different medicine can be an option. Those are decisions for your prescriber.
What people report
In online communities, people on GLP-1 medicines trade nausea tips constantly. The themes people commonly describe are eating something small before getting out of bed, keeping crackers or similar bland food nearby, cutting greasy and fried food, stopping at the first sign of fullness, and sipping instead of gulping. Many describe the day after an injection or a dose increase as the hardest, and some describe a food they loved suddenly turning them off.
People also mention ginger chews, peppermint, anti-nausea prescriptions and spreading the dose increase out longer.
None of this was measured. People who find a trick are more likely to post it, and the people it did not help rarely say so. It is here because these methods are everywhere, not because they are proven.
When it needs a call
- Vomiting that keeps going or fluids you cannot keep down. Both labels warn that dehydration from digestive losses can cause kidney injury.
- Severe or constant stomach pain, which can be a sign of pancreatitis or gallbladder trouble. The labels list both.
- Anyone with diabetes who uses insulin or a sulfonylurea, since eating less can change the dose they need.
- Anyone who is not eating enough for days, who should ask about the dose, anti-nausea medicine or a dietitian.
Questions to bring to a clinician or dietitian
- Can we slow the dose increases if nausea is hard to live with?
- Is an anti-nausea medicine safe with my other medicines?
- Which symptoms mean I should call you or be seen right away?
- What should I do if I cannot keep fluids down?
What is still unknown
- Whether any specific food change reduces nausea on these medicines is untested in trials.
- Whether ginger, peppermint or acupressure bands help beyond placebo in this group is unknown.
- Why some people have far more nausea than others is not well understood.
Related pages
Sources
- Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus Gorgojo-Martínez JJ, et al. J Clin Med. 2023;12(1):145. PMID 36614945. Funding: Not stated in the abstract. Journal article
- Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society Mozaffarian D, et al. Obes Pillars. 2025;15:100181. PMID 40673264. Funding: Professional societies; several authors report industry relationships. Journal article
- Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials Rubino DM, et al. Diabetes Obes Metab. 2025;27(4):1826-1835. PMID 39789843. Funding: Eli Lilly. Journal article
- Wegovy (semaglutide) injection and tablets: prescribing information Novo Nordisk, on DailyMed (U.S. National Library of Medicine). Label version 6/2026. One label covers both the injection and the tablets. Official FDA label on DailyMed
- Zepbound (tirzepatide) injection: prescribing information Eli Lilly and Company, on DailyMed (U.S. National Library of Medicine). Label version 8/2026. Official FDA label on DailyMed